
 <b>Regulatory Policy Committee</b>	<b>OPINION</b>	
<b>Impact Assessment (IA)</b>	The Veterinary Medicines Regulations 2013	
<b>Lead Department/Agency</b>	Department for Environment, Food and Rural Affairs	
<b>Stage</b>	Final	
<b>Origin</b>	European	
<b>IA number</b>	DEFRA 1442	
<b>Date submitted to RPC</b>	16/04/2013	
<b>RPC Opinion date and reference</b>	16/05/2013	RPC12-DEFRA-1504(2)
<b>OITO Assessment</b>	<b>GREEN</b>	
<p>The IA says the “<i>OITO and the moratorium on micro-businesses do not apply as the VMR is implementing Directive 2001/82 (as amended). Similarly changes to fees and charges are out of scope with respect to OITO and the moratorium</i>”.</p> <p>As there is no evidence of going beyond minimum European requirements this is in accordance with the Better Regulations Framework Manual (paragraph 2.9.8 ii &amp; ix). In addition, as the only aspects of the proposals that have a cost to business are in relation to fees and charges (which are also out of scope of OITO) no equivalent annual net cost to business figure in OITO terms is required.</p>		
<p><b>Overall quality of the analysis and evidence presented in the IA</b>  <i>Impact on businesses.</i> Although the IA sets out, on the summary table of costs and benefits on page 17, the impact of the changes to industry as a whole, it would benefit from setting out the impact across various business sub-sectors within the veterinary industry, and an idea of any secondary impacts that increased fees might have on those sectors.</p>		
<b>Signed</b> 	<b>Michael Gibbons, Chairman</b>	